Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition

Search Radius:25 Miles

5
10
15
20
25
30
40
50
100
500
All

We've found

2,533

archived clinical trials in

Kidney Cancer

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Saint Michael's Hospital

mi

from

Stevens Point, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Green Bay Oncology - Sturgeon Bay

mi

from

Sturgeon Bay, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Aurora Medical Center in Summit

mi

from

Summit, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Vince Lombardi Cancer Clinic

mi

from

Two Rivers, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Aurora Cancer Care-Waukesha

mi

from

Waukesha, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Waukesha Memorial Hospital ProHealth Care

mi

from

Waukesha, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Aspirus Regional Cancer Center

mi

from

Wausau, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Aurora Cancer Care-Milwaukee West

mi

from

Wauwatosa, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Aurora West Allis Medical Center

mi

from

West Allis, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

The Alyce and Elmore Kraemer Cancer Care Center

mi

from

West Bend, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Diagnostic and Treatment Center

mi

from

Weston, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Marshfield Clinic - Weston Center

mi

from

Weston, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Marshfield Clinic - Wisconsin Rapids Center

mi

from

Wisconsin Rapids, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Riverview Hospital

mi

from

Wisconsin Rapids, WI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Rocky Mountain Oncology

mi

from

Casper, WY

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Cheyenne Regional Medical Center-West

mi

from

Cheyenne, WY

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Big Horn Basin Cancer Center

mi

from

Cody, WY

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Billings Clinic-Cody

mi

from

Cody, WY

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Welch Cancer Center

mi

from

Sheridan, WY

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Larry G Strieff MD Medical Corporation

mi

from

Oakland, CA

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Community Cancer Center Foundation

mi

from

Normal, IL

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Lankenau Medical Center

mi

from

Wynnewood, PA

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

San Juan City Hospital

mi

from

San Juan,

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Oncare Hawaii Inc-Pali Momi

mi

from

'Aiea, HI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Pali Momi Medical Center

mi

from

'Aiea, HI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Leeward Radiation Oncology Center

mi

from

'Ewa Beach, HI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

UC Comprehensive Cancer Center at Silver Cross

mi

from

New Lenox, IL

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Union Hospital of Cecil County

mi

from

Elkton, MD

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Lakeland Hospital

mi

from

Saint Joseph, MI

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Novant Health Oncology Specialists-Statesville

mi

from

Statesville, NC

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

Wright-Patterson Medical Center

mi

from

Wright-Patterson Air Force Base, OH

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Status: Enrolling
Updated: 12/31/1969

UPMC-Coraopolis/Heritage Valley Radiation Oncology

mi

from

Moon, PA

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma

Status: Enrolling
Updated: 12/31/1969

University of Texas M.D. Anderson Cancer Center

mi

from

Houston, TX

Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma

Status: Enrolling
Updated: 12/31/1969

University of Texas M.D. Anderson Cancer Center

mi

from

Houston, TX

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Los Angeles, CA

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Tampa, FL

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

New York, NY

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Portland, OR

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Seattle, WA

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Hackensack, NJ

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Louisville, KY

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Rochester, MN

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Oklahoma City, OK

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Hershey, PA

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Overland Park, KA

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Cleveland, OH

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

mi

from

Nashville, TN

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

Status: Enrolling
Updated: 12/31/1969

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

mi

from

East Bentleigh,

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (Prostate, Bladder and Kidney)Cancers

Status: Enrolling
Updated: 12/31/1969

National Institutes of Health Clinical Center, 9000 Rockville Pike

mi

from

Bethesda, MD

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy

Status: Enrolling
Updated: 12/31/1969

M D Anderson Cancer Center

mi

from

Houston, TX